{
    "clinical_study": {
        "@rank": "141126", 
        "arm_group": [
            {
                "arm_group_label": "Hepastem Low dose", 
                "arm_group_type": "Experimental", 
                "description": "12.5x106cells/kg"
            }, 
            {
                "arm_group_label": "Hepastem Intermediate dose", 
                "arm_group_type": "Experimental", 
                "description": "50x106cells/kg"
            }, 
            {
                "arm_group_label": "Hepastem High dose", 
                "arm_group_type": "Experimental", 
                "description": "200x106cells/kg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and to appraise the efficacy of one cycle\n      of Hepastem (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC) infusions up\n      to twelve months in paediatric patients suffering from CN or UCD."
        }, 
        "brief_title": "Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Urea Cycle Disorders,", 
            "Crigler Najjar Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Crigler-Najjar Syndrome", 
                "Urea Cycle Disorders, Inborn", 
                "Cardiomyopathies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The subject is 18 years or older at time of screening.\n\n          2. The subject presents acute liver failure.\n\n          3. The subject presents clinical or radiological evidence of liver fibrosis or cirrhosis\n\n          4. The subject presents or has a history of hepatic or extrahepatic malignancy\n\n          5. The patient has a non-corrected cardiac malformation.\n\n          6. The subject has a known medical or family history of coagulopathy.\n\n          7. The subject participates currently in another clinical trial - except disease\n             registry and observational HepaStem study.\n\n          8. The subject underwent previous mature liver cell or stem cell transplantation or\n             received an organ liver transplant.\n\n          9. The subject has a contraindication to immunosuppressive therapy.\n\n         10. The subject has a known hypersensitivity or allergy to the recommended antibiotics to\n             prevent post-operative infections according to institutional guidelines, and\n             basiliximab, solumedrol or tacrolimus unless alternative drugs can be used without\n             risk for the patient.\n\n         11. The subject has a known hypersensitivity or allergy to bivalirudin.\n\n         12. The subject had or has a renal insufficiency treated by dialysis.\n\n         13. The subject requires valproate therapy.\n\n         14. The subject has a known hypersensitivity or allergy to contrast agents that cannot be\n             treated adequately.\n\n         15. The subject has a thrombosis of the portal vein or persisting impairment of\n             anterograde portal blood flow.\n\n         16. The subject has a porto systemic shunt or fistula assessed by Doppler US.\n\n         17. For umbilical vein access: The subject has any contraindication for umbilical vein\n             catheterization (eg omphalitis, peritonitis, necrotizing enterocolitis, etc)\n\n         18. Any significant condition which in the Investigator's opinion may interfere with the\n             subject's optimal participation in the study.\n\n         19. Patients with disease of such severity that liver transplantation is an absolute\n             indication.\n\n         20. Patients with mild disease severity, easily controlled under standard of care therapy\n             with no recurrent metabolic crises."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01765283", 
            "org_study_id": "HEP001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Hepastem Low dose", 
                "Hepastem Intermediate dose", 
                "Hepastem High dose"
            ], 
            "intervention_name": "HepaStem", 
            "intervention_type": "Biological", 
            "other_name": "HHALPC,Heterologous Human Adult Liver derived Progenitor Cells"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CN,", 
            "UCD"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }, 
                    "name": "Saint Luc University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "2650"
                    }, 
                    "name": "Universitair Ziekenhuis (UZ) Antwerpen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }, 
                    "name": "Universitair Ziekenhuis (UZ) Gent"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Le Kremlin Bic\u00eatre Cedex", 
                        "country": "France", 
                        "zip": "94275"
                    }, 
                    "name": "CHU Bic\u00eatre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille Cedex", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "H\u00f4pital Jeanne de Flandre, CHRU Lille"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13385"
                    }, 
                    "name": "H\u00f4pital de la Timone, CHU de Marseille"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse cedex 9", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "H\u00f4pital des Enfants, CHU de Toulouse"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "31096"
                    }, 
                    "name": "Rambam Medical Center, Meyer Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel", 
                        "zip": "91240"
                    }, 
                    "name": "Hadassah Ein-Kerem Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Petach Tikva", 
                        "country": "Israel", 
                        "zip": "49202"
                    }, 
                    "name": "Schneider Children's Medical Center of israel"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "zip": "00165"
                    }, 
                    "name": "Ospedale Pediatrico Bambino Gesu di Roma"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "zip": "B4 6NH"
                    }, 
                    "name": "Birmingham Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "WC1N 3JH"
                    }, 
                    "name": "Great Ormond Street Hospital London"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France", 
                "Israel", 
                "Italy", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Prospective, Open Label, Multicenter, Partially Randomized, Safety Study of One Cycle of Promethera HepaStem in Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Paediatric Patients.", 
        "other_outcome": {
            "description": "liver biopsy ,Enzymatic activity (quantitative) on the biopsies or, Donor sequences by RT PCR or in situ hybridisation (FISH) or immunohistochemistry.", 
            "measure": "characterize the engraftment capacity of HHLAPC for both indications", 
            "safety_issue": "No", 
            "time_frame": "baseline, and 6 month (optional at 12 month FU"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Italy: Istituto Superiore di Sanit\u00e0", 
                "Israel: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Assessed by physical exam, vital signs , Clinical Lab tests and Morphology of liver, bile ducts and portal system by ultrasound", 
                "measure": "Adverse events and serious adverse events related to infusion and concomitant treatment", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 month post infusion"
            }, 
            {
                "description": "Reactogenicity of infusion,short and mid term safety of infusion", 
                "measure": "Safety of the technical intervention", 
                "safety_issue": "Yes", 
                "time_frame": "During 6 months for four time windows"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01765283"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Physical examination, Vital signs,Clinical laboratory tests of liver enzymes, renal function, coagulation factors, hematology,Level of anti-HLA and other auto-immune markers, Adverse events and serious adverse events related to infusion and concomitant treatments", 
                "measure": "long-term safety profile of HepaStem for both indications", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 months post infusion"
            }, 
            {
                "measure": "preliminary efficacy of HepaStem for both indications (CN and UCD) and for different weight cohorts", 
                "safety_issue": "No", 
                "time_frame": "0-6 months, 6-12 months"
            }
        ], 
        "source": "Promethera Biosciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Promethera Biosciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}